EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC 4.0

GP Consultations for Herpes Zoster After COVID-19 Vaccination: A Self-Controlled Cohort Study Based on Electronic Health Record Data from the Netherlands

Rana Jajou, Eugène van Puijenbroek, Jetty Overbeek, Karin Hek, Erik Mulder, Florence van Hunsel, Agnes Kant

Drug Safety · 2026

DOI: 10.1007/s40264-025-01638-2 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Drug Safety, 2026. Verfasst von Rana Jajou und 6 weiteren Autor:innen. Beteiligte Einrichtung: Netherlands Pharmacovigilance Centre Lareb, Goudsbloemvallei 7, 's-Hertogenbosch, The Netherlands. Hauptthemen laut MEDLINE: Electronic Health Records, COVID-19 Vaccines, Herpes Zoster, COVID-19. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ministerie van Volksgezondheid, Welzijn en Sport.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND OBJECTIVE: Several systematic reviews and meta-analyses have been published with conflicting results on the risk of herpes zoster after coronavirus disease 2019 (COVID-19) vaccination. We aimed to study the risk of herpes zoster after COVID-19 vaccination using electronic health record data of general practices, from a large cohort in the Netherlands. METHODS: Persons aged ≥ 12 years who received at least one COVID-19 vaccination and were registered in the general practice databases of PHARMO and Nivel Primary Care Database were included. This study used a self-controlled design comparing the risk of herpes zoster in the risk period (28 days after COVID-19 vaccination) with the control period. Poisson regression was used to calculate incidence rate ratios, adjusting for severe acute respiratory syndrome coronavirus 2 infection. RESULTS: There were 2,098,683 COVID-19 vaccinated persons aged ≥ 12 years included, of whom 1,058,646 (50.4%) were female. An increased risk for herpes zoster was found after all the doses grouped together and the third dose of all COVID-19 vaccination (adjusted incidence rate ratio: all doses 1.07, 95% confidence interval [CI] 1.02-1.13 and third dose 1.21, 95% CI 1.05-1.38). After stratification on vaccine type, all doses and the third dose of messenger RNA vaccination (adjusted incidence rate ratio: all doses 1.06, 95% CI 1.00-1.12 and third dose 1.21, 95% CI 1.05-1.40) showed an increased risk. CONCLUSIONS: Our study showed a slight increased risk of herpes zoster when taking into account all doses and all types of vaccines. After stratification on vaccine type, no increased risk of herpes zoster after the primary vaccination series and a slightly elevated risk after the third/booster vaccination with a messenger RNA vaccine were found.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Electronic Health RecordsCOVID-19 VaccinesHerpes ZosterCOVID-19HumansNetherlandsFemaleMaleAgedMiddle AgedCohort StudiesAdultAdolescentYoung AdultChildVaccinationIncidenceAged, 80 and over

Substanzen

COVID-19 Vaccines

Autor:innen und Institutionen

  • Netherlands Pharmacovigilance Centre Lareb, Goudsbloemvallei 7, 's-Hertogenbosch, The Netherlands.
  • Department of PharmacoTherapy, Epidemiology and Economics, Groningen Research Institute of Pharmacy (GRIP), University of Groningen, Groningen, The Netherlands.
  • PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands.
  • Nivel (Netherlands Institute for Health Services Research), Utrecht, The Netherlands.
  • Netherlands Pharmacovigilance Centre Lareb, Goudsbloemvallei 7, 's-Hertogenbosch, The Netherlands. f.vanhunsel@lareb.nl.
  • Department of PharmacoTherapy, Epidemiology and Economics, Groningen Research Institute of Pharmacy (GRIP), University of Groningen, Groningen, The Netherlands. f.vanhunsel@lareb.nl.

Förderung

  • Ministerie van Volksgezondheid, Welzijn en Sport

Zitieren

APA

Jajou, R., van Puijenbroek, E., Overbeek, J., Hek, K., Mulder, E., van Hunsel, F., & Kant, A. (2026). GP Consultations for Herpes Zoster After COVID-19 Vaccination: A Self-Controlled Cohort Study Based on Electronic Health Record Data from the Netherlands. Drug Safety. https://doi.org/10.1007/s40264-025-01638-2

Vancouver

Jajou R, van Puijenbroek E, Overbeek J, Hek K, Mulder E, van Hunsel F, et al. GP Consultations for Herpes Zoster After COVID-19 Vaccination: A Self-Controlled Cohort Study Based on Electronic Health Record Data from the Netherlands. Drug Safety. 2026. doi:10.1007/s40264-025-01638-2

BibTeX
@article{Jajou2026,
  author = {Jajou, Rana and van Puijenbroek, Eugène and Overbeek, Jetty and Hek, Karin and Mulder, Erik and van Hunsel, Florence and Kant, Agnes},
  title = {GP Consultations for Herpes Zoster After COVID-19 Vaccination: A Self-Controlled Cohort Study Based on Electronic Health Record Data from the Netherlands},
  journal = {Drug Safety},
  year = {2026},
  doi = {10.1007/s40264-025-01638-2}
}
Kostenlos starten →